Nevirapine Versus Efavirenz – Based Antiretroviral Therapy Regimens for TB – HIV Coinfected in Paholpolpayuhasena Hospital

Abstract

Objective: To compared increase level of CD₄ in TB – HIV coinfected who had sputum positive and sputum negative for TB between antiretroviral therapy with Nevirapine group (NVP) and Efarivenz group (EFV)
Method: This was descriptive and retrospective analysis of adult who diagnosed TB - HIV coinfected viral load < 20 copies/ml in Paholpolpayuhasena Hospital between 1 January 2012 to 31 December 2015. The data were separated into patients with sputum positive and sputum negative for
TB in the NVP group and EFV group. Mean CD₄ increase was analyzed using unpaired t-test.
Result: Patients with sputum positive for TB who received NVP based regimen had mean CD₄ increase 140.93 cell/mm³ while who received EFV based regimen had mean CD₄ increase 153.00 cell/mm³ (t-test = 0.2477 p-value = 0.8072). Patients with sputum negative for TB who received NVP based regimen had mean CD₄ increase 132.31 cell/mm³ while who received EFV based regimen had mean CD₄ increase 89.24 cell/mm³ (t-test = 0.9380 p-value = 0.3589).
Conclusion: There were no significant differences in increase level of CD₄ in TB – HIV coinfected who had sputum positive and sputum negative for TB in NVP group and EFV group of antiretroviral therapy in patient who had VL <20 copies/ml.